REG - ReNeuron Group plc - Notice of Results

ReNeuronAnnouncement

20/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220620:nRST3705Pa&default-theme=true

RNS Number : 3705P  ReNeuron Group plc  20 June 2022

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Notice of Results

Analyst meeting and Investor presentation

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes
Technologies, will announce its preliminary results for the year ended 31
March 2022 on Monday 4 July 2022.

 

Analyst briefing

Iain Ross, Chairman, Catherine Isted, Chief Financial Officer and Dr Randolph
Corteling, Vice President of Research will be hosting a briefing for analysts
which will take place in the City of London on Monday 4 July 2022 at 13.00
(BST) / 08:00 (ET). A Zoom link will also be available for those unable to
attend the meeting in-person.

 

For more information and to register to attend the meeting in-person or to
receive the Zoom link, please email reneuron@walbrookpr.com or call +44 (0)20
7933 8785.

 

Investor Briefing

Management will also be hosting a live online presentation relating to the
preliminary results via the Investor Meet Company platform at 15.00 on Monday
4 July. The presentation is open to all existing and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and register for the
presentation here:

https://www.investormeetcompany.com/reneuron-group-plc/register-investor
(https://www.investormeetcompany.com/reneuron-group-plc/register-investor)

 

Investors who already follow ReNeuron on the Investor Meet Company platform
will automatically be invited.

 

Questions can be submitted pre-event via your IMC dashboard or in real time
during the presentation, via the "Ask a Question" function.  Whilst the
Company may not be in a position to answer every question it receives, it will
address the most prominent within the confines of information already
disclosed to the market through regulatory notifications. A recording of the
presentation, a PDF of the slides used, and responses to the Q&A session
will be available on the Investor Meet Company platform afterwards.

 

ENDS

 

 

Contacts:

 

 ReNeuron                                          www.reneuron.com/investors (http://www.reneuron.com/investors)
 Iain Ross, Chairman                               Via Walbrook PR
 Catherine Isted, Chief Financial Officer

 Liberum Capital Limited (NOMAD and Joint Broker)  +44 (0)20 3100 2000

 Phil Walker (Investment Banking)

 Richard Lindley (Investment Banking)

 Ben Cryer (Investment Banking)

 Allenby Capital Limited (Joint Broker)            +44 (0)20 3328 5656
 James Reeve/George Payne (Corporate Finance)
 Stefano Aquilino (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)          +44 (0)20 7933 8780 or reneuron@walbrookpr.com
 Paul McManus/Alice Woodings                       +44 (0)7980 541 893/+44 (0)7407 804 654

 

 

About ReNeuron

ReNeuron is a UK based Proprietary Stem Cell based Exosome Technologies
company, harnessing its unique stem cell technologies to develop 'off the
shelf' treatments for diseases with significant unmet needs.

 

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a
delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins,
small molecules and genes. The Company has a growing number of partner
collaborations with Global Pharma, Biotech and academic partners in this
fast-expanding area of scientific and commercial interest. ReNeuron also has
the ability, through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform, to make allogeneic tissue cells of choice and has the
potential to produce exosomes with tissue specific targeting ability.

 

The Company has out-licenced its CTX Programme for stroke disability and hRPC
programme in retinitis pigmentosa to Fosun in China and is looking to
out-licence both these programmes in other territories.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORQDLFFLQLBBBL